XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Segment Information
 6 Months Ended
Jun. 30, 2024
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates its business and reports its results through three operating and reportable segments: dispensary, patient services, and clinical trials & other in accordance with ASC 280. See Note 2 for a summary of the Company’s policy on segment information.
Summarized financial information for the Company’s segments is shown in the following tables:
(in thousands)Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Revenue
Patient services$52,461 $53,426 $104,914 $103,699 
Dispensary44,440 25,196 84,119 49,436 
Clinical trials & other1,677 1,602 4,211 3,281 
Consolidated revenue$98,578 $80,224 $193,244 $156,416 
Direct costs
(in thousands)Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Patient services$46,522 $44,878 $96,019 $87,692 
Dispensary38,801 20,111 71,610 39,256 
Clinical trials & other229 118 620 252 
Total segment direct costs$85,552 $65,107 $168,249 $127,200 
Depreciation expense
Patient services$500 $446 $1,015 $852 
Dispensary30 29 61 45 
Total segment depreciation expense$530 $475 $1,076 $897 
Amortization of intangible assets
Patient services$719 $676 $1,437 $1,351 
Clinical trials & other55 53 110 105 
Total segment amortization$774 $729 $1,547 $1,456 
Operating income
Patient services$4,720 $7,426 $6,443 $13,804 
Dispensary5,609 5,056 12,448 10,135 
Clinical trials & other1,393 1,431 3,481 2,924 
Total segment operating income$11,722 $13,913 $22,372 $26,863 
Goodwill impairment charges
Patient services$— $— $— $16,235 
Clinical trials & other— — — 632 
Total impairment charges$— $— $— $16,867 
Selling, general and administrative expense$27,872 $28,726 $56,324 $57,556 
Non-segment depreciation and amortization214 125 384 245 
Total consolidated operating loss$(16,364)$(14,938)$(34,336)$(47,805)
(in thousands)June 30, 2024December 31, 2023
Assets   
Patient services$70,709 $73,551 
Dispensary17,353 8,378 
Clinical trials & other10,017 8,878 
Non-segment assets81,523 118,433 
Total assets$179,602 $209,240